Skip to main content

Market Overview

Satsuma Pharma Opens Above IPO Price


Satsuma Pharma (NASDAQ: STSA) made its public debut Friday morning, opening at $19 after being priced in the range of $14-$15 per share.

Satsuma has listed its shares on the Nasdaq under the ticker symbol "STSA."

Satsuma Pharma IPO: What You Need To Know

Founded in June 2016, Satsuma is a clinical-stage biopharma company developing a novel therapeutic product for the acute treatment of migraines.

Its product candidate STS101 is a drug-device combination of a proprietary dry powder formulation of dihydroergotamine mesylate, or DHE, for quick and easy administration using a pre-filled, single-use, nasal delivery device.

Credit Suisse, SVB Leerink and Evercore are the underwriters for the offering.


Related Articles (STSA)

View Comments and Join the Discussion!

Posted-In: News IPOs

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at